Sabby Management’s Blueprint Medicines BPMC Stock Holding History

Sabby Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-50,000	Closed	-$2M	–	224
2017 Q1	$2M	Buy	+50,000	New	+$1.79M	0.11%	92
2016 Q2	–	Sell	-29,624	Closed	-$535K	–	299
2016 Q1	$535K	Buy	+29,624	New	+$514K	0.03%	204
2015 Q4	–	Sell	-308,504	Closed	-$6.95M	–	329
2015 Q3	$6.58M	Buy	308,504 +6,700	+2%	+$185K	0.27%	61
2015 Q2	$8M	Buy	+301,804	New	+$8.62M	0.29%	69

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Sabby Management's BPMC Position: Q2 2017 in Review

Sabby Management sold out of Blueprint Medicines (BPMC) in Q2 2017, closing a stake of 50,000 shares — an estimated $2M sold.

Sabby Management first reported a position in BPMC in Q2 2015 and held it in 4 quarters. The position peaked at $8M in Q2 2015. 124 funds tracked by Wall St. Rank hold BPMC as of Q2 2017.

Sabby Management reported no remaining Blueprint Medicines position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 50,000 Blueprint Medicines shares in Q2 2017, an estimated $2M.
Sabby Management first reported a position in Blueprint Medicines in Q2 2015 and held it in 4 quarters.
Sabby Management's Blueprint Medicines position peaked at $8M in Q2 2015.
124 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.